Literature DB >> 7575268

Effect of intravitreal dexamethasone in treatment of pneumococcal endophthalmitis in rabbits.

S S Park1, N Samiy, K Ruoff, D J D'Amico, A S Baker.   

Abstract

PURPOSE: To investigate whether corticosteroid therapy would decrease the inflammation and tissue damage associated with pneumococcal endophthalmitis.
METHODS: Albino rabbits were injected intravitreally with 1000 live organisms of Streptococcus pneumoniae and randomized after 24 hours to treatment with intravitreal vancomycin hydrochloride alone (n = 10), combination intravitreal vancomycin and intravitreal dexamethasone (n = 10), or no treatment (n = 10). After 2 weeks, the eyes were examined clinically and enucleated for histopathologic examination.
RESULTS: Eyes treated with vancomycin and dexamethasone had significantly less intraocular inflammation and more preservation of retinal tissue than untreated eyes or eyes treated with vancomycin alone (P < .05, Fisher's exact test). Untreated and vancomycin-treated eyes were indistinguishable on clinical and histologic examination. Marked anterior and posterior segment inflammation with total retinal necrosis was noted in eyes from both groups.
CONCLUSION: Intravitreal corticosteroid therapy may play an important role in minimizing the inflammation and tissue damage associated with pneumococcal endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575268     DOI: 10.1001/archopht.1995.01100100112040

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  14 in total

1.  Intraocular dexamethasone produces a harmful effect on treatment of experimental Staphylococcus aureus endophthalmitis.

Authors:  T A Meredith; H E Aguilar; C Drews; A Sawant; S Gardner; L A Wilson; H E Grossniklaus
Journal:  Trans Am Ophthalmol Soc       Date:  1996

Review 2.  [Treatment of postoperative endophthalmitis : Operate or only inject?]

Authors:  L Mautone; C Skevas; M S Spitzer
Journal:  Ophthalmologe       Date:  2021-02-10       Impact factor: 1.059

3.  Daptomycin versus vancomycin in a methicillin-resistant Staphylococcus aureus endophthalmitis rabbit model: bactericidal effect, safety, and ocular pharmacokinetics.

Authors:  Sophie Lefèvre; Maher Saleh; Luc Marcellin; Audrey Subilia; Tristan Bourcier; Gilles Prévost; François Jehl
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 4.  Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis.

Authors:  Diem K Bui; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

Review 5.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

Review 6.  Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions.

Authors:  Michelle C Callegan; Michael Engelbert; David W Parke; Bradley D Jett; Michael S Gilmore
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

7.  Role of hemolysin BL in the pathogenesis of extraintestinal Bacillus cereus infection assessed in an endophthalmitis model.

Authors:  M C Callegan; B D Jett; L E Hancock; M S Gilmore
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

8.  Pathogenesis of gram-positive bacterial endophthalmitis.

Authors:  M C Callegan; M C Booth; B D Jett; M S Gilmore
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

9.  Intravitreal human immune globulin in a rabbit model of Staphylococcus aureus toxin-mediated endophthalmitis: a potential adjunct in the treatment of endophthalmitis.

Authors:  Dennis P Han
Journal:  Trans Am Ophthalmol Soc       Date:  2004

10.  Toward improving therapeutic regimens for Bacillus endophthalmitis.

Authors:  Brandt J Wiskur; Michael L Robinson; Allison J Farrand; Billy D Novosad; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.